Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 1  
  
CLINICAL STUDY PROTOCOL  
 
The Thromboxane  Receptor  Antagonist to Block the Effects of Non-P latelet 
Thromboxane Generation and Improve Endothelial Function (TRAP) Trial  
 
 
Protocol  Number:  H00017901 
 
Principal  Investigator:  Jeffrey J. Rade, MD  
University of  Massachusetts Medical School 
65 Lake Avenue North, Room H2- 46, 
Worcester, MA 01655  
Phone: 774- 441-6310  
FAX: 774- 441-6305  
jeffrey.rade@umassmed.edu  
 
Investigational  Drug:  Ifetroban Oral  Capsule  
IND Number:  138088 
 
ClinicalTrials.gov  Identifier:  [STUDY_ID_REMOVED] 
 
Study  Sponsor:  American Heart  Association 
7272 Greenville  Avenue  
Dallas, TX  75231  
 
Protocol  Version  Date:   August 16, 2022 
 
 
 
 
THIS DOCUMENT IS CONFIDENTIAL AND FOR THE SOLE INFORMATION AND USE OF 
THE INVESTIGATOR’S RESEARCH TEAM AND THE APPOINTED INSTITUTIONAL  
REVIEW BOARD.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 2  
 
Approvals and Revision History 
 
 
 
Approved By  
Name  Title  Signature  Date  
Jeffrey J. Rade, MD  Professor of Medicine   October 31, 2020  
  
   
 
Revision History  
Version Number  Date  
01 May 20,  2019  
Initial  Release  
02 July 29,  2019  
Amendment  1 
03 February 3, 2020  
04 October 31, 2020  
05 August 16, 2022  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 3  
 Table of Contents  
Appr ovals and Revision History  ..................................................................................................... 2 
Table of  Contents  ............................................................................................................................ 3 
PROTOCOL  SUMMARY .................................................................................................................... 6 
ABBREVIATIONS  ............................................................................................................................... 9 
1 Background  ............................................................................................................................11 
1.1 Overview of  Thromboxane  Biology  ..................................................................................11 
1.2 Thromboxane  Receptor Biology  ........................................................................................11 
1.3 TXA 2  Generation and  Clinical Outcome  .......................................................................... 12 
1.4 Factors Associated with Non -platelet  TXA2  Generation  .................................................. 13 
1.5 Oxidative Stress Stimulates TXA 2  Generation in  Endothelial  Cells  ................................. 14 
1.6 Non-platelet Thromboxane Generation and Atherothrombosis  ........................................ 15 
1.7 Renal Effects of TXA 2  and TPr Inhibition ........................................................................ 16 
1.8 Summary of Mechanistic Hypothesis Tested in this Study  ............................................... 16 
2 Ifetroban.  ............................................................................................................................... 17 
2.1 Pharmacology .................................................................................................................... 17 
2.2 Pre-Clinical and  Human Studies  ....................................................................................... 17 
2.3 Bleeding  Risks  .................................................................................................................. 17 
2.4 Effect on Blood Pressure and Renal  Function .................................................................. 18 
2.5 Heart  Failure  ..................................................................................................................... 18 
3 Study  Objectives .................................................................................................................... 18 
4 Study Design  ......................................................................................................................... 19 
4.1 Screening  Phase  ................................................................................................................ 19 
4.2 Randomization  .................................................................................................................. 19 
4.3 Study  Interventional  Phase ................................................................................................ 19 
4.3.1 Study Visit 1 (Baseline Day  0, Outpatient)  ....................................................................19 
5 Study Population and Eligibility  Criteria  .............................................................................. 20 
5.1 Study  Population ............................................................................................................... 20 
5.2 Inclusion Criteria  ............................................................................................................... 20 
5.3 Exclusion Criteria  ............................................................................................................. 20 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 4  
 6 Recruitment and  Screening  Procedures  ................................................................................. 21 
6.1 Common Recruitment Procedures  .................................................................................... 21 
6.2 Estimated  Enrollment Period  ............................................................................................ 21 
6.3 Informed  Consent Procedures  ........................................................................................... 21 
6.4 Confidentiality and HIPAA  Requirements  ........................................................................ 21 
6.5 Protection of  Human Subjects  ........................................................................................... 21 
6.6 Summary of Risks  and Benefits  ........................................................................................ 21 
6.6.1 Risks  ...............................................................................................................................21 
7 Study  Drug  Handling ............................................................................................................. 22 
7.1 Drug  Dispensing ............................................................................................................... 22 
7.2 Drug Storage, Accountability  and Destruction  ................................................................. 22 
7.3 Emergency  Unblinding ..................................................................................................... 22 
8 Outcome  Determinations ....................................................................................................... 22 
8.1 Primary  Endpoint  .............................................................................................................. 22 
8.2 Secondary  Endpoints  ......................................................................................................... 22 
8.3 Exploratory  Endpoints  ...................................................................................................... 23 
9 Subject  Safety  ........................................................................................................................ 23 
9.1 Institutional Review  Board  ............................................................................................... 23 
9.2 Food and Drug  Administration  ......................................................................................... 23 
9.3 Independent Clinical  Event  Adjudicator  ........................................................................... 23 
9.4 Adverse  Events  ................................................................................................................. 24 
9.4.1 Definitions  ......................................................................................................................24 
9.4.2 Recording and Reporting of  Adverse  Events  .................................................................25 
9.4.3 Suspected Unexpected Serious  Adverse  Reaction  .........................................................26 
10 Statistical Considerations  ...................................................................................................... 26 
10.1 Sample  Size Calculations  .................................................................................................. 26 
10.1.1 Primary  Endpoint  ...........................................................................................................26 
10.1.2 Secondary  Endpoints  ......................................................................................................26 
10.2 Statistical Analysis Plan  .................................................................................................... 27 
11 Data Management  ................................................................................................................. 27 
12 Regulatory  Issues  .................................................................................................................. 27 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 5  
 12.1 Ethics and Good Clinical Practice  .................................................................................... 27 
12.2 Institutional Review  Board  ............................................................................................... 27 
12.3 Informed  Consent  .............................................................................................................. 27 
12.4 Quality Control  and Assurance  ......................................................................................... 28 
13 References  ............................................................................................................................. 29 
14 Appendix A: Table of Study  Events  ...................................................................................... 34 
15 Appendix B:  Brachial Reactivity  .......................................................................................... 35 
15.1 Introduction ....................................................................................................................... 35 
15.2 Protocol  ............................................................................................................................. 35 
15.2.1 Subject  preparation  ........................................................................................................35 
15.2.2 Conduct of the Brachial Reactivity  Study  ......................................................................36 
15.3 Representative Result s ...................................................................................................... 37 
16 Appendix C: Peripheral  Arterial  Tonometry  ......................................................................... 37 
16.1 Introduction ....................................................................................................................... 37 
16.2 Protocol  ............................................................................................................................. 38 
16.2.1 Subject  Preparation  ........................................................................................................38 
16.2.2 Prepare the Endo- PAT System  for Study  ........................................................................39 
16.2.3 Conduct of the  Endo- PAT Study  ....................................................................................39 
16.2.4 Review  and Analysis  ......................................................................................................40  
16.3 Representative Results  ...................................................................................................... 41 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 6  
 PROTOCOL SUMMARY  
 
 
Title of Study  The Thromboxane Receptor Antagonism to Blunt the Effects of  Non- 
Platelet Thromboxane Generation and Improve Endothelial Function 
(TRAP) Trial  
Protocol Number  H00017901  
Investigational Drug  Ifetroban Oral Capsules  
Drug Manufacturer  Cumberland Pharmaceuticals Inc.  
 
 
 
 
 
Objectives  The objectives of this study are:  
 
To determine if thromboxane receptor antagonism improves 
endothelial function in subjects with non- platelet thromboxane 
generation.  
 
To determine if thromboxane receptor antagonism reduces non - 
platelet thromboxane generation.  
 
To determine if thromboxane receptor antagonism reduces oxidative stress, inflammation and thrombotic potential.  
 
To determine if thromboxane receptor antagonism alters renal prostaglandin secretion and improves renal function.  
 
 
 
Study Design  This is a phase 2b, single center, prospectively randomized, double - 
blinded, placebo- controlled clinical trial conducted at the UMass 
Medical School/UMass Memorial Medical Center.  
 
Subjects with cardiovascular disease on standard aspirin therapy with elevated non -platelet thromboxane generation defined by urine 
thromboxane B
2 metabolites >1145 pg/mg creatinine will be 
randomized to receive either ifetroban 250 mg capsules once daily or matching placebo.  
Number of Subjects  57 subjects randomized 1:1 to ifetroban or placebo.  
Treatment Duration  4 weeks  
 
Study Endpoints  The primary trial endpoint will be the change from baseline in 
Reactive Hyperemia Index (RHI) measured by peripheral arterial tonometry (PAT).  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 7  
  
 Secondary trial endpoints will be the change from baseline in on - 
treatment: 1) % flow -mediated vasodilation (FMD),and; 2) urine 11-  
dhTXB 2. 
Exploratory trial endpoints will be the change from baseline in on - 
treatment: 1) urine 8 -iso-PFG 2α; 2) plasma tissue factor; 3) plasma 
ICAM -1; 4) plasma activated protein C; 5) hs -CRP; 6) NT pro -BNP;  
7) urine 2,3- dinor -6-ketoPGF 1α and ratio of 11- dhTXB 2 to 2,3- dinor - 
6-ketoPGF 1α; 8) urine TXB 2, 6-ketoPGF 1α and the ratio o f TXB 2 to 6-  
ketoPGF 1α, and; 9) glomerular filtration rate.  
 
 
Inclusion Criteria  Males and females 18 -80 years of age with established cardiovascular 
disease who take ≥81 mg daily of aspirin and have thromboxane B 2 
metabolites >1145 pg/mg creatinine on screening.  
 
Able to provide written consent and comply with protocol -specific 
procedures.  
 
 
 
 
 
 
 
 
Exclusion Criteria  Chronic oral anticoagulation with non -vitamin K antagonist.  
 
Anticipated change or interruption in aspirin therapy during the study 
period. 
 
ST segment myocardial infarction within the past 30 days. 
Cardiac surgery within the past 30 days.  
Stage 4 -5 renal failure or on renal replacement therapy. 
An ongoing uncontrolled severe inflammatory condition. Pregnant, intending to become pregna nt or breast feeding. 
Known ifetroban or aspirin sensitivity  
Inability to perform vascular testing.  
 
Participation in another investigational drug trial within 30 days of 
randomization. 
 
Safety Evaluation  Safety assessments will be performed at all study visits and will 
include physical examination and vital signs (blood pressure, pulse rate, respiration rate).  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 8  
  
 
Statistical Methods  Descriptive statistics of patient characteristics will be generated using 
conventional methods. Continuous data will be compared between 
treatment groups using ANCOVA. Dichotomous data will be compared using chi -square analysis with a Yate’s correction.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 9  
  
 
Abbreviation  Definition  ABBREVIATIONS  
8-iso-PGF 2α isoprostane generated by free radical peroxidation of  arachidonate  
AA arachidonic acid  
ACS  acute coronary  syndrome  
ADP  adenosine  diphosphate  
AE adverse event  
AERD aspirin exacerbated respiratory  disease 
ANCOVA analysis of  covariance  
ASA acetylsalicylic acid,  aspirin  
BMS  Bristol Myers  Squibb 
BUN  blood urea  nitrogen  
CABG  coronary artery bypass  graft  
CAD coronary arterial  disease  
CEA 
CHARISMA  Clinical Events Adjudicator  
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance  
COX cyclooxygenase one (prostaglandin- endoperoxide synthase or PTGS) 
CPI Cumberland Pharmaceuticals  Inc. 
CVD cardiovascular  disease  
EC ECC  endothelial cell  
endocardial endothelial cell  
ELISA  enzyme -linked immunosorbant assay 
FDA  Food and Drug  Administration  
FHS 
FMD  Framingham Heart Study 
flow mediated dilation  
FRIMS  Flexible Randomization and Inventory Management  System 
GFR  glomerular filtration  rate 
HOPE  Heart Outcomes Prevention Evaluation 
HR hazard  ratio  
hs-CRP  high sensitivity C -reactive protein 
HUVEC  human umbilical vein endothelial cells 
ICAM -1 intracellular adhesion molecule one 
ID identification  
ife-AG ifetroban  acylglucuronide  
IND Investigational N ew Drug  
INR International Normalized  Ratio  
IPr IRB prostaglandin I
2 (prostacyclin) receptor 
institutional review board  
IsoP isoprostane  
IUPAC  International Union of Pure and Applied  Chemistry 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 10  
 IV intravenous  
kd dissociation constant  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 11  
 Abbreviation  Definition  
kg kilogram  
L liter 
LC-MS/MS  Liquid chromatography -tandem mass spectrometry 
LnRHI  log transformed Reactive Hyperemia  Index  
LVEF  
µg left ventricular ejection fraction 
microgram  
µM micromole  
mg milligram 
MI myocardial infarction  
min minute  
mL milliliter  
mM millimolar  
N number  
nM nanomolar  
NO nitric  oxide  
NT pro-BNP  N terminal pro -brain natriuretic protein 
NYHA  New York Heart  Association  
PAH  pulmonary arterial  hypertension  
PCI percutaneous coronary  intervention  
PGF 1α prostaglandin F1α 
PGF 2α prostaglandin F2α 
PGH 2 prostaglandin H 2 
PGI 2 prostaglandin I 2, prostacyclin  
PVD peripheral vascular disease 
REDCap  Research Electronic Data  Capture  
RHI RIGOR ROS  Reactive Hyperemia Index  
Reduction in Graft Occlusion Rate study reactive oxygen species  
SAE  serious adverse  event  
SAR  serious adverse  reaction  
SMC  smooth muscle  cell 
STEMI  ST segment elevation myocardial  infarction 
t½ plasma terminal elimination  half-life 
TNF -α tumor necrosis  factor --α 
TPr thromboxane prostanoid receptor  
TXA
2 thromboxane  A2 
TXAS TXB
2 
TXB 2-M thromboxane synthase thromboxane B
2 
thromboxane B 2-metbolites  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 12  
 1 Background  
1.1 Overv iew of Thromboxane  Biology 
Thromboxane A 2 (TXA 2) is a signal -activated 
eicosanoid generated from the metabolism of 
arachidonic acid (AA) via the actions of the 
cyclooxygenase (COX) and downstream 
thromboxane synthase (TXAS) enzymes.4 In 
healthy adults, the vast majority of TXA 2 is 
produced in platelets, where it not only mediates 
activation of the platelet in which it is formed, but is also released to locally amplify thrombotic 
stimuli by directly  activating adjacent platelets 
and causing potent vasoconstriction.
5 Aspirin 
(ASA) exerts its antiplatelet effect by irreversibly inhibiting the COX -1 enzyme for the life of the 
platelet, thereby suppressing platelet TXA
2 
generation and activation. In path ologic conditions such as cardiovascular disease (CVD), TXA 2 
generation increases substantially in non- platelet tissues such as endothelial cell (EC) and in 
inflammatory cells (Figure 1) . Unlike platelet- derived TXA 2, standard doses of ASA are 
ineffective at suppressing non- platelet- derived TXA 2 due to the short circulating half -life of ASA 
(t1/2 ~20 min), the ability of nucleated cells to regenerate COX -1 and formation of TXA 2 mediated 
by COX -2, which unlike COX -1 is not effectively inhibited by ASA . 
 
TXA 2 is a short -lived molecule (t 1/2 ~30 sec) that undergoes aqueous nucleophilic attack to form 
thromboxane B 2 (TXB 2), an inert eicosanoid that circulates in the bloodstream. TXB 2 itself is 
extensively metabolized via enzyme- mediated β -oxidation and dehydroge nation to dozens of 
inactive end -order metabolites (TXB 2-M) that are concentrated in the urine (Figure 1).6 
Measurement  of one of these stable  urine  metabolites,  11-dehydroTXB 2 (11-dhTXB 2) was initially 
developed as a clinical indicator of ASA responsiveness based on data showing that  ASA 
suppressed urine 11- dhTXB 2 to <400 pg/mg creatinine in >90% of healthy adults.7 With the 
realization that non -platelet sources generate substantial amounts of TXA 2 in pathologic 
conditions, urine 11- dhTXB 2 is now considered a reflection of systemic non- renal TXA 2 
generation. (TXA 2 generated by the renal glomeruli undergoes limited metabolism prior to 
secretion, thus urine TXB 2 is considered reflective of renal -specific TXA 2 generation.8) 
 
1.2 Thromboxane Receptor  Biology 
The biologic activity of TXA 2 is mediated through the binding to the thromboxane -prostanoid 
receptor  (TPr),  a G-protein coupled transmembrane protein present  on a diverse  array  of cell types, 
including EC, vascular smooth muscle cells (SMC) and cardiac myocytes.9-12 Two isoforms exist 
that can form  heterodimers, TPα, which  is widely  distributed, and TPβ, which  is restricted  to limited 
cell types such as EC.13 High -affinity ligands for TPr are TXA 2 and PGH 2 (Kd 6.19- 16 nM), but 
isoprostanes such as 8 -isoPGF 2α that form non -enzymatically from arachidonic acid under 
conditions of oxidative stress, are also physiologically important ligands (K d 31.8 nM).14 Key 
cellular effects of TPr activation are shown in Table 1. In whole blood vessel preparations , TPr 
activation inhibits nitric oxide (NO) production and endothelial -dependent vasodilation.15 Several  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Sources of TXA 2 generation.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 13  
 reports have shown that TPr activation not only 
increases superoxide generation but oxidative stress 
increases transport and stabilization of both TPr 
isoforms  on cell membranes.16-18 In general, the TXA 2- 
TPr pathway’s pro- coagulant, pro- inflammatory and 
vasoconstrictor effects counterbalance and in some 
cases directly antagonize the anti -coagulant, ant - 
inflammatory and vasodilating effects of prostacyclin 
(PGI 2) and NO. Table 1. Cellular effects of TPr 
activation.9, 11, 15 -26 
 
1.3 TXA 2 Generation and Clinical  
Outcome 
Several studies have shown that elevated urine levels 
of TXA 2 metabolites  in patients  with CVD  on standard 
ASA therapy is associated with an increased risk of 
atherothrombotic events and death.3, 27 -30 Sub- studies 
from the HOPE and CHARISMA trials found that in 
patients with/high risk for CVD on ASA, those with 
urine TXB 2-M in the highest quartile had a ~1.7- fold 
increased risk of death, myocardial infarction (M I) or 
stroke  compared  those  in the lowest  quartile.27, 29 Early  
interpretation of these results was that ASA  failed to adequately inhibit platelet COX -1 activity in 
a subset  of patients  with CVD,  leading  to persistent  TXA 2 generation,  increased  platelet  reactivity 
and atherothrombosis. It is now understood  that ASA is actually  very effective at inhibiting  platelet 
TXA 2 generation and that the observed persistent TXA 2 generation originates from non-platelet 
tissue that cannot be inhibited by standard ASA  therapy.  
 
This concept was definitively demonstrated in the Reductions in Graft Occlusion Rates (RIGOR) 
study.3 Given  that ASA reduces  the rate of vein graft  (VG)  thrombosis  by 50% after coronary  artery 
bypass graft (CABG) surgery31, the RIGOR study hypothesized that failure of ASA to inhibit 
platelet activation would increase the prevalence of VG occlusion 6 months after CABG surgery. 
ASA responsiveness was assessed both by urine 11- dhTXB 2, which measures non- renal systemic 
TXA 2 generation, and by AA -induced platelet aggregation, which specifically assesses platelet 
TXA 2 generation. Similar to other studies32-35, the RIGOR study found that ASA suppressed 
platelet TXA 2 generation in 95% and 99% of subjects 3 days and 6 months after CABG surgery, 
respectively. However, urine 11- dhTXB 2 was also elevated in 70% and 33% of subjects at these 
same time points, often to high levels (Figure 2A). While no association was found between the failure  of ASA to suppress  platelet  TXA
2 generation  and VG thrombosis, 11-dhTXB 2 ≥450 pg/mg 
creatinine measured  6 months  after  surgery  was independently  associated  with VG occlusion (OR 
2.6, P<0.02; Figure 2B) compared to values <450 pg/mg creatinine.3 In an analysis of long -term 
outcome, 11- dhTXB 2 ≥450 pg/mg creatinine in 288 RIGOR subjects with suppressed platelet 
TXA 2 generation independently predicted 5- year MACE (adjusted HR 1.79, P=0.02) and death 
(adjusted  HR 2.90, P =0.01)  compared  to lower  values  (Figure  3).1 These data provide  compelling 
evidence that, in patients  with CVD,  unlike  healthy  individuals, there is substantial  TXA 2 Cell Type  Physiologic Effect  
Platelet ↑Shape change,  
↑Aggregation  
SMC  ↑Contraction, ↑Hypertrophy,  
↑Proliferation  
Myocyte  ↑Apoptosis, ↑Arrhythmia  
EC ↓NO, ↑ROS, ↑Adhesion 
Molecules, ↑Tissue Factor  
Leukocyte  ↑Activation, ↑Adhesion 
Molecules, ↑Tissue Factor  
Lymphocyte  ↑Cytokine release, ↓Acquired 
Immunity  
 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 14  
 generation from non- platelet sources that is not suppressed by standard ASA therapy and is a 
potent risk factor for atherothrombosis and death. 
 
 
To determine if TXA 2 generation  predicts 
outcome  in a large unselected  population, 
TXB 2-M was recently measured 3042 
subjects participating in Exam 8 
Offspring and Exam 3 Omni cohorts of the Framingham Heart Study (FHS). The 
median urine TXB
2-M in the 
1361subjects on ASA and the 1681 
subjects not on ASA were 1145 and  4179 
pg/mg creatinine, respectively. 
Regardless of ASA use, urine TXB 2-M 
above the respective median values was 
associated with more than a two -fold risk 
of long -term mortality (Figure 4; Rade, 
unpublished data).  
 
These data indicate that systemic TXA 2 
generation is a potent risk factor for  
mortality, not only in patients with established CVD, but also in a general population and is independent of ASA use.  
 
1.4 Factors Associated with Non -platelet TXA2  Generation  
Multivariable mod elling of RIGOR subjects with documented ASA -mediated suppression of 
platelet TXA 2 generation identified independent risk factors for non- platelet TXA 2 generation 
(Table 2).2 Oxidative stress, as measured by urine 8 -isoPGF 2α, was identified as the stronges t risk 
factor for non -platelet TXA 2 generation, accounting for nearly half of the modelled effect (Figure  
 
 
 
 
 
 
 
 
Figure 2 . A. Urine 11- dhTXB 2 in RIGOR subjects 3 
days and 6 months after CABG surgery.3 Red line 
denotes 400 pg/mg creatinine. B . Percentage of 
occluded SVG 6 months after surgery in 229 subjects 
stratified by quartile of 11- dhTXB 2. 3 
 
 
 
 
 
 
 
 
 
 
Figure 3. 5-year survival of 288 RIGOR 
subjects stratified by urine 11- dhTXB 2 <450 
pg/mg creatinine (red line) or above (blue  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Long -term survival in 2727 FHS subjects 
stratified by mean urine TXB 2-M. 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 15  
 5). In addition to being a marker for  
oxidative stress, 8- iso-PGF 2α is also a  
stable circulating eicosanoid capable of 
activating TPr to cause vasoconstriction 
and potentiate agonist -induced platelet 
activation.36 Other independent risk 
factors are shown in Table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5 Oxidative Stress Stimulates TXA 2 Generation in Endothelial Cells  
While the predominant eicosanoid produced in healthy EC is PGI 2, TXA 2, is induced in 
dysfunctional EC where it counteracts the vasodilator effects of PGI 2 and nitric oxide (NO), thus 
impairing endothelial- dependent vasodilatation.37, 38 Oxidative stress, a major mediator of EC 
dysfunction39, stimulates TXA 2 and isoprostane generation in human EC (Figure 6A)2. Similar to 
porcine cerebral and retinal microvessels 40, 41, macrovascular EC generates substantial amounts 
of TXA 2 when directly stimulated with 8 -iso-PGF 2α (Figure 6B), an effect that is inhibited by TPr 
blockade (Figure 6C). Furthermore, 8 -isoPGF 2α may not be the most physi ologic relevant 
isoprostane species to mediate this effect. For example, oxidative stress also results in formation 
of isothromboxanes, which would be expected to bind TPr more avidly than 8- isoPGF 2α.42 These 
data suggest that EC under oxidative stress are a potentially major source of non- platelet TXA 2 
generation  and that autocrine/paracrine  stimulation  of the TP receptor  by TXA 2 and/or  isoprostanes 
amplify this process. Furthermore, they identify TP receptor blockade as a promising strategy to not only bl ock the effects of TXA
2 but also inhibit its  generation.  
Urine 8 -iso 
PGF 2α (ln pg/mg 
creatinine)  
Age (years)  
Female gender  
White race 
(versus non - 
white)  
Statin therapy  
(mg/dL)  
LVEF (%)  
ASA dose (81mg 
vs. >81 mg)  
*Normalized using natural log transform  
Weight  
p-value  
Coefficient  
Table 2. Independent risk factors for UTXB 2* 
identified by multivariable regression analysis.  
 
 
 
 
 
 
 
 
 
 
Figure 5. Linear regression of urine 11-  
dhTXB 2 to 8-isoPGF 2α in 228 subjects 
with suppressed platelet TXA 2 
generation .2 0.442  <0.001  0.472  
 
0.239  <0.001  0.102  
0.129  0.015  0.093  
-0.172  0.009  0.085  
-0.161  0.004  0.077  
-0.152  0.002  0.072  
-0.113  0.032  0.048  
-0.145  0.004  0.052  
 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 16  
  
 
 
1.6 Non-platelet Thromboxane Generation and  Atherothrombosis 
Little is known about how non- platelet TXA 2 generation increases cardiovascular risk. While 
ASA- inhibited platelets could potentially still respond to non- platelet -derived TXA 2, in the 
RIGOR cohort 11- dhTXB 2 and 8- isoPGF 2α were independent of any tested parameter of platelet 
function3 and in the CHARISMA trial the  addition of clopidogrel  did not  reduce adverse events  in 
subjects with elevated 11 -dhTXB 2.29 These data argue against non -platelet- derived TXA 2 or 
circulating 8 -iso-PGF 2α mediating thrombosis in vivo by “priming” or potentiating platelet 
reactivity.  
 
Stronger evidence exists for non- platelet TXA 2 and 8- iso-PGF 2α generation promoting 
atherothrombosis and impairing EC thromboresistance. In apo E -deficient mice, for example, 
atherogenesis is inhibited by the administration of a TP receptor antagonist but not by ASA.43 
Preliminary data reveal that TPr stimulation with isoprostane induces expression of multiple 
adhesion molecules in EC (Figure 7A; Rade unpublished data). TPr activation has been shown by 
others t o potentiate cytokine -mediated TF expression in endothelial cells and monocytes19, 44 and 
TF is also directly  upregulated  by oxidative  stress (Figure  7B; Rade  unpublished data).  Additional 
evidence indicates  that TPr inhibition  blunts  cytokine -mediated  TXA2  generation  (Figure  7C) and 
downregulation of thrombomodulin (TM), the key component of the protein C anticoagulant 
pathway that is critical for maintaining thromboresistance (Figure 7D; Rade unpublished  data).45- 
 
 
 
 
 
 
 
 
Figure 6. A . Oxidative stress induced by hydrogen peroxide (H 2O2) increases generation of 8 -isoPGF 2α, 11- 
dhTXB 2 and TXB 2 measured by LC -MS/MS in the supernatants of human umbilical vein endothelial cells 
(HUVEC).2 B. Direct exposure of HUVEC to 8- isoPGF 2α increases generation of TXB 2 measured by LC - 
MS/MS. C . TPr antagonism with SQ 29,548 (10-6M) inhibits HUVEC TXB 2 generation in response to 8-  
isoPGF 2α (10-6M) as measured by ELISA.  
 
 
 
 
 
 
 
 
Figure 7. A . Isoprostanes stimulate adhesion molecule expression by HUVEC. B. Oxidative stress induced by 
1-hour incubation with 200 μM H 2O2 stimulates tissue factor expression in HUVEC. C. Cytokine -induced 
TXA2 generation in HUVEC is inhibited by TP receptor antagonism with SQ 29548. D . TP receptor 
antagonism with SQ 29548 blunts  cytokine -mediated TM downregulation in HUVEC.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 17  
 48 These data suggest  that autocrine/paracrine  TPr activation  by TXA 2 and/or  isoprostane  alter EC 
thromboresistance and provide the rationale using a TPr antagonist to reduce the risk of 
atherothrombosis. 
 
1.7 Renal Effects of TXA 2 and TPr  Inhibition  
Prostaglandins  play an important  role in regulating  renal  blood flow  and kidney  function. The TPr 
is expressed in multiple places within the kidney (glomerulus, renal arterioles, thick ascending 
loop of Henle, collecting ducts and convoluted tubules) and renal TXA 2 generation is thought t o 
play a role in regulating renal blood flow and glomerular filtration.49, 50 TPr antagonism has been 
shown to inhibit renal vasoconstriction and prevent kidney injury in endotoxemic mice.51 In 
diabetic apolipoprotein E -deficient mice, TPr antagonism was s hown to attenuate oxidative stress 
and proteinuria.52 In patients  with cyclosporin -induced renal  toxicity,  infusion of a TXAS  inhibitor 
reduced renal TXA 2 generation and improved glomerular filtration.53 These data suggest TPr 
inhibition  could potentially  improve  renal  function  in patients  with CVD and increase non-platelet 
TXA 2 generation, especially those with heart  failure.  
 
1.8 Summary of Mechanistic Hypothesis Tested in this Study  
Clinical and in vitro  experimental  data point  to oxidative  stress as a potent  stimulus  for endothelial 
TXA 2 generation. TXA 2 generation by vascular EC is hypothesized to be both a manifestation as 
well as a mediator of endothelial dysfunction. This provides the rationale for TPr antagonism as  a 
means of improving vascular fun ction. Figure 8 depicts a mechanistic model encompassing these 
concepts. Key features of the model  include:  
• Oxidative stress stimulates TXA 2 generation and inhibits PGI 2 generation by; 1) enhancing  
COX- 1 activity and altering the relative activities of TXA S to prostacyclin synthase (PGIS), 
and; 2) non- enzymatic formation of  isoprostanes.  
• Autocrine/paracrine activation of  
the TPr by TXA 2 and/or  
isoprostanes; 1) potentiates  
TXA 2 generation via a positive  
feedback loop; 2) induction of 
adhesion molecules and other inflammatory mediators, and; 3) impairs thromboresistance by stimulating TF expression and inhibiting the TM -APC 
anticoagulant  pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Proposed model for the effects of oxidative stress and 
mechanical stretch on EC/EEC eicosanoid generation and change 
in cellular phenotype. IsoP=  isoprostane; ROS= reactive oxygen 
species; AA= arachidonic acid; TM= thrombomodulin; TF= 
tissue factor; APC= activated protein C.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 18  
 2 Ifetroban.  
2.1 Pharmacology 
Ifetroban is a small potent and selective antagonist of the TPr with a molecular weight of 462.5 
kD (Figure 9). Though readily absorbed after oral dosing, absorption is delayed after a meal and thus should be given to patie nts 30 minutes or more prior to a meal. Ifetroban has a plasma half - 
life of approximately 22 hours. Elimination is primarily by metabolism and biliary excretion.  
 
Each capsule contains 250 mg of ifetroban. Other ingredients 
include mannitol, microcrystalline cellulose, crospovidone, 
magnesium oxide, colloidal silicon dioxide, and magnesium stearate. Capsules are filled into high density polyethylene bottles and sealed with screw -cap closures. Placebo for 
ifetroban capsules are formulated as a dry powder bl end filled 
into capsules with similar matrix. Available data suggest the capsules will be stable for at least 48 months. A complete description of the pharmacology and toxicology of ifetroban is provided in the Investigator’s Brochure.  
2.2 Pre-Clinical and Hum an Studies  
Ifetroban was initially developed for cardiovascular indications involving atherothrombosis and 
ischemia.54 It has been the subject of extensive pre -clinical and clinical testing including eight 
randomized, placebo- controlled clinical trials in various cardiovascular indications, several of 
which included daily ifetroban oral doses of 250 mg for more than two weeks in subjects taking 
ASA.  Ifetroban  was well-tolerated  in clinical studies  with a cumulative  enrollment of nearly  1,300 
ifetroban- exposed subjects. Doses as high as 1000 mg were administered to healthy volunteers 
with no serious adverse  events. 
 
Ifetroban is currently under study for the treatment of several non- cardiac conditions including 
systemic  sclerosis  with and without  pulmonary  hypertension, ASA exacerbated  respiratory  disease, 
hepatorenal syndrome, portal hypertension and prevention of tumor metastases. By virtue of its 
direct TPr blocking effect and its potential ability to reduce TXA 2 generation by inhibiting a 
positiv e feedback loop involving the TPr, ifetroban is an ideal candidate to mitigate the effects of 
as well as potentially reduce non -platelet TXA 2 generation. A complete description of the pre - 
clinical and clinical experience with ifetroban, including extensiv e safety data is provided in the 
Investigator’s  Brochure.  
2.3 Bleeding Risks 
Ifetroban, by virtue of its ability to block the effects of TXA 2, has similar effects on platelet 
function and hemostasis as ASA, which exerts its effects by inhibiting TXA 2 generation. In 
subjects already on ASA therapy, the addition of ifetroban does not further impair platelet or 
hemostatic function and does not increase the risk of bleeding 
 
TXA 2 is only one of several platelet agonists that play an important role in hemos tasis. Platelet 
function studies  reveal  that ifetroban  blocks  platelet activation  by AA and TXA 2 but not in response 
to ADP,  thrombin or collagen.  Thus, bleeding  risk in subjects  taking  ifetroban  plus dual antiplatelet 
 
 
 
 
 
 
 
 
Figure 9 . Structural formula of 
ifetroban.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 19  
 therapy (ASA + ADP receptor antagonist) would not be expected to be greater than in subjects 
taking dual antiplatelet therapy alone.  
 
In a study of 17 subjects on stable warfarin therapy, the addition of 250 mg/d ifetroban for 7 days 
did not alter the INR (BMS Internal Repor t). The available clinical data has not demonstrated an 
increase in hemorrhagic events, though the number of subjects taking ifetroban and warfarin are limited (see Investigator’s Brochure for details). The interaction of ifetroban and novel oral anticoagu lants has not been studied. 
 
2.4 Effect on Blood Pressure and Renal  Function  
TXA 2, through its activation  of the TPr, is a potent  vasoconstrictor. While  ifetroban  has been  shown 
in pre -clinical animal models to reverse the hypertensive effects of infusions of arachidonic acid, 
it has not been shown to have significant hypotensive or adverse renal effects in humans: the incidence of hypotension  and renal  failure  in all studies  was <0.5%  and not different  with placebo 
treatment (see Investigator’s Brochure for  details).  
2.5 Heart Failure  
While ifetroban has not yet been studied specifically in a heart failure population, many of the subjects enrolled in the historic cardiovascular trials had recent myocardial infarctions and would have been expected to have had a diminished LVEF. In over 1500 subjects studied with 
cardiovascular  disease,  the incidence of new heart  failure  was low (≤1%) and no different  between 
ifetroban and placebo treated  subjects.  
 
3 Study  Objectives  
This study  will test the hypothesis  that administration  of the TPr recepto r antagonist  ifetroban  will 
improve endothelial function by blocking the effects and generation of TXA 2 from non- platelet 
sources.  
 
The objectives of this study are:  
 
• To determine if thromboxane receptor antagonism improves endothelial function in 
subjects  with non- platelet thromboxane  generation.  
• To determine if thromboxane receptor antagonism reduces non -platelet thromboxane 
generation.  
• To determine if thromboxane receptor antagonism reduces oxidative stress, inflammation 
and thrombotic  potential.  
• To dete rmine if thromboxane receptor antagonism alters renal prostaglandin secretion 
and improves renal  function. 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 20  
 4 Study  Design  
The TRAP study is a phase 2b, single center, prospectively randomized, double -blinded, placebo - 
controlled outpatient clinical trial conducted at the UMass Medical School/UMass Memorial 
Medical  Center.  A schedule of  study  events is  outlined in  Appendix  A. 
4.1 Screening Phase  
Patients with established cardiovascular disease on ≥81 mg daily ASA as part of their normal therapeutic regimen will be screened for non -platelet TXA
2 generation by measuring urine TXB 2 
metabolites using either the AspirinWorks 11-dehydro Thromboxane B 2 Test Kit (Corgenix Inc., 
Bromfield, CO) or the essentially identical 11 -dehydro Thromboxane B 2 ELISA Kit (Cayman 
Chemical,  Ann Arbor,  MI). Those  with normalized  values  ≥1145 pg/mg creatine and who meet  all 
other inclusion/exclusion criteria will be eligible for  participation.  
 
Urine TXB 2-M measured as part of a related on -going observational study of this same patient 
population under separate consent may be used to determine eligibility for this randomized trial. 
4.2 Randomization  
Eligible subjects will be randomized to receive either five 50 mg ifetroban oral capsules (250 mg total does)  daily  or matching  placebo  in a 1:1 ratio for 4 weeks.  Double -blind  randomization will 
occur at the first study visit using the UMass Flexible Randomization and Inventory Management System  (FRIMS).  
 
4.3 Study Interventional  Phase  
4.3.1 Study Visit 1 (Baseline Day 0,  Outpatient) 
• If not already done prior to this visit, subjects will be consented for the  study.  
• Compliance with uninterrupted daily aspirin use for the preceding 5 days will be  verified.  
• Baseline physical exam will be performed, vital signs will be  recorded.  
• Concomitant medications will be  recorded.  
• Baseline urine and blood samples will be  obtained.  
• Subjects will undergo baseline vascular  testing.  
• Subjects will be  randomized. 
• Subjects will be provided study drug enough for 35 days and instructed to take one pill 
daily. They will be instructed to continue all other medications, especially aspirin, as 
prescribed by their physician and to avoid unnecessary changes to their medical  regimen.  
 
4.3.1.1  Study Visit 2 (Interim Day 7 ± 3 Days, Phone  Contact)  
• Subjects will be contacted app roximately 1 week after starting study drug to monitor  for 
compliance and possible adverse events (AE).  
 
4.3.1.2  Study Visit 3 (Follow -up Day 28 ± 3 Days,  Outpatient)  
• Subjects will take study drug on the day of the  visit.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 21  
 • Subjects will bring in unused study drug and pill counts will be  performed.  
• Physical exam will be performed, vital signs will be  recorded.  
• Concomitant medications will be  recorded.  
• Subjects will be assessed for possible  AE. 
• On-drug urine and blood samples will be  obtained.  
• On-drug physical exam with vital signs will be  performed.  
• On-drug vascular studies will be  performed.  
 
4.3.1.3  Study Visit 4 (Day 42 ± 3 Days, Phone  Contact)  
• Subjects will be contacted 2 weeks after stopping study drug to monitor for possible  AE. 
 
5 Study Population and Eligibility  Criteria  
5.1 Study  Population  
Patients suitable for this protocol are individuals with cardiovascular disease on standard aspirin 
therapy with elevated non -platelet thromboxane generation.  
 
5.2 Inclusion  Criteria  
1. Males and females 18 -80 years of age wi th established cardiovascular disease, defined by 
either:  
a. Angiographic (invasive or non- invasive) evidence of coronary  atherosclerosis.  
b. Prior myocardial  infarction. 
c. Positive stress test with documented peripheral or cerebrovascular  disease.  
2. Taking ≥81 mg daily ASA as part of their standard medical  regimen.  
3. Urine TXB 2-M >1145 pg/mg creatinine during  screening.  
4. Able to provide written consent and comply with protocol -specific procedures.  
 
5.3 Exclusion  Criteria 
1. Chronic oral anticoagulation with a non- vitamin K  antagonist.  
2. Anticipated change or interruption in aspirin therapy during the study  period.  
3. STEMI within 30 days.  
4. Cardiac surgery within 30 days.  
5. Stage 4 -5 kidney failure or on renal replacement  therapy.  
6. An uncontrolled ongoing severe inflammatory  condition.  
7. Pregnant, intending to become pregnant or breast feeding. (All women of child- bearing 
potential must have a negative pregnancy test within 24 hours of  randomization.)  
8. Known ifetroban or aspirin sensitivity.  
9. Inability to perform vascular testing or comply  with study  protocol.  
10. Participation in another investigational drug trial within 30 days of  randomization.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 22  
  
 
6 Recruitment and Screening Procedures  
6.1 Common Recruitment  Procedures  
Patients referred to the UMass Memorial Medical Center Heart and Vascular Interventional 
Laboratory for clinically -indicated cardiac catheterization who are participating in an ongoing 
observational clinical study (IRB #H00014594_3) will form the major screening population for 
this interventional trial. As part of this observational study, non-platelet thromboxane generation 
is assessed  in each subject  by measuring  urine  TXB 2-M. Subjects  not participating  in this screening 
study but who otherwise meet all the inclusion/exclusion criteria will be eligible to participate in 
this interventional  trial.  
 
6.2 Estimated Enrollment  Period  
This study will enroll a maximum of 57 subjects over a period of 30 months. 
 
6.3 Informed Consent Procedures  
Designated  study  personnel  will explain  to eligible  subjects  the purpose  of the study,  interv entions, 
risk and benefits of participation and will answer questions. Wherever possible, subjects will be provided a copy of the UMass IRB approved consent form to review in advance of meeting with study  personnel. All subjects  who sign consent  forms  will be provide  a full copy  of the signed  and 
executed  document. 
 
6.4 Confidentiality and HIPAA Requirements  
All information collected on study participants will be stored in a confidential manner. Only approved study personnel will have access to data collected as part of the study. Consented study participants will be identified by a participant ID number on all study documents. Data will be stored securely using procedures described under Data Management.  
 
6.5 Protection of Human  Subjects  
Protections for human subj ects of research are required under Department of Health and Human 
Services regulations in 21 CFR parts 50, 56, and 312. 
 
6.6 Summary of Risks and  Benefits  
6.6.1 Risks 
6.6.1.1  Drug -related  
Given its established safety profile, especially in patients with high -risk cardiovas cular 
disease, the risks associated with ifetroban administration are expected to be minimal (see above section 2 and Investigator’s Brochure). Given that both ifetroban and ASA inhibit 
TXA
2-mediate platelet activation, they have similar antiplatelet effects and bleeding risk.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 23  
 Administration  of ifetroban  to subjects  already  taking  ASA has not been  shown  to increase 
the risk of bleeding as the TXA 2 pathway in platelets is already maximally  suppressed.  
6.6.1.2  Blood  draws  
The risks of drawing blood include bleeding at the puncture site, bruising and pain. These 
would be expected to occur in a very small portion of the population. 
6.6.1.3  Vascular Studies  
The risks  of vascular  studies  include  discomfort  in the arm during prolonged blood pressure 
cuff inflation.  
 
7 Study Drug Handling  
7.1 Drug Dispensing  
50 mg ifetroban oral capsules and matching placebo will be provided by Cumberland Pharmaceuticals Inc. and packaged by the UMass Investigational Pharmacy into plastic bottles containing 175 pills. Bottle labe ls will contain instructions to take one pill daily in the morning, 
the name  and contact  information  of the PI as well as a code that can be used in case of emergency 
unblinding. 
 
7.2 Drug Storage, Accountability and  Destruction  
Study product will be stored prior to dispensing at the UMass Investigational Pharmacy at room temperature. Unused study drug will be returned by subjects at Visit 3 and disposed of by the UMass Investigational Pharmacy, which will hold all destruction documentation. 
 
7.3 Emergency Unblin ding  
The UMass Investigational Pharmacy will maintain a log of study product codes that can be  used 
in the unlikely event that emergency unblinding is  required.  
 
 
8 Outcome Determinations 
8.1 Primary Endpoint  
The primary  trial endpoint  will be change  from  baseline in on-treatment  Reactive Hyperemia Index 
(RHI) measured by peripheral arterial tonometry (PAT) using the standard protocol described in 
Appendix C  . 
 
8.2 Secondary Endpoints  
Secondary trial endpoints will be the change from baseline in on- treatment: 
 
• Brachial % flow -mediated vasodilation (FMD) using the standard protocol described in 
Appendix  B. 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 24  
 • Urine 11- dhTXB 2 as measured by mass spectrometry or immunoassay and normalized to  
urine  creatinine.  
 
8.3 Exploratory Endpoints  
Exploratory trial endpoints will be the change from baseline in on- treatment: 
 
• Urine 8 -iso-PFG 2α as measured by immunoassay and normalized to urine  creatinine.  
• Plasma tissue factor as measured by  immunoassay. 
• Plasma ICAM -1 as measured by  immunoassay.  
• Plasma activated protei n C as measured by  immunoassay.  
• hs-CRP as measured by  immunoassay.  
• NT pro -BNP as measured by  immunoassay.  
• Urine 2,3- dinor -6-ketoPGF 1α and ratio of 11- dhTXB 2 to 2,3- dinor -6-ketoPGF 1α as 
measured by immunoassay and normalized to urine  creatinine.  
• Urine TXB 2, 6-ketoPGF 1α and the ratio of TXB 2 to 6-ketoPGF 1α ketoPGF 1α as measured  
by immunoassay and normalized to urine  creatinine.  
• Glomerular filtration rate as calculated by the Cockroft- Gault  formula.  
 
9 Subject  Safety  
9.1 Institutional Review  Board  
The Study Protocol, Investigator Brochure, consent form, Investigational New Drug application 
(IND) and other relevant documents will be submitted to the UMass IRB for approval prior to commencement of the trial. Any amendment other than minor administrative changes , must be 
reviewed and approved by the IRB before implementation. 
 
9.2 Food and Drug  Administration  
Use of ifetroban in this clinical trial is covered under an approved IND application to the US Food and Drug Administration (FDA).  
 
9.3 Independent Clinical Event  Adjudicator  
An independent Clinical Event Adjudicator, with expertise in the field of cardiology will be identified and trained on the study protocol and Investigator Brochure prior to the first subject enrollment in this study. The role of this CEA is to provide an independent, expert review of data on clinical events based on protocol specific definitions outlined below.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 25  
 9.4 Adverse  Events  
9.4.1 Definitions 
9.4.1.1  Adverse  Event  
An adverse event  (AE) is any untoward medical  occurrence associated  with the use of a drug 
in a participant, whether or not considered drug or biologic related. An AE can therefore be 
any undesirable  sign,  symptom  or medical  condition occurring  after starting  study  drug,  even 
if the event  is not considered to be related  to the pharmaceutical  product. Study  drug includes 
the drug under evaluation, and any reference or placebo drug given during any phase of the trial. 
9.4.1.2  Suspected Adverse  Reaction  
A suspected adverse reaction (SAR) is any adverse event for which there is a reasonable 
possibility that the drug caused the event. “Reasonable possibility” suggests there is a causal 
relationship between the drug and the adverse event. “Suspected adverse reaction” implies a lesser degree of certainty about causality than adverse reaction, w hich means any adverse 
event caused by a drug.  
9.4.1.3  Serious Adverse Events  (SAE)  
An adverse event or suspected adverse reaction is considered serious if the investigator or sponsor believes any of the following outcomes occurred:  
• Death  
• Life-threatening AE: Plac es the participant at immediate risk of death at the time of 
the event as it occurred. It does not include an AE that, had it occurred in a more 
severe form, might have caused  death.  
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal life  functions. 
• Inpatient hospitalization or prolongation of  hospitalization.  
• Results in congenital anomaly or birth  defect.  
• Important medical events that may not result in death, be life threatening, or require hospitalization ma y be considered a serious adverse event when, based upon 
appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition  above. This determination  is based  on the opinion of either  the investigator 
or sponsor (e.g., if either believes it is serious, it must be considered serious).  
 
9.4.1.4  Laboratory Test Abnormalities 
For laboratory test abnormalities that meet the definition of an SAE, that required the participant to have the investigational product discontinued or interrupted or required the 
participant to receive specific corrective therapy, the clinical diagnosis rather than the laboratory term will be used by the reporting investigator (e.g., anemia ve rsus low 
hemoglobin value).  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 26  
 9.4.1.5  Assessment of Causal Relationship  
A medically -qualified investigator must assess the relationship of any AE to the use of study 
drug, based on available information, using the following guidelines:  
• Not related: The re is not a reasonable causal relationship to the investigational 
product and the adverse  event. 
• Unlikely related: No temporal association or the cause of the event has been 
identified, or the drug or biologic cannot be  implicated.  
• Possibly related: There is reasonable evidence to suggest a causal relationship between the drug and adverse event.  
• Related:  There is evidence to suggest  a causal  relationship, and the influence  of other 
factors is unlikely. 
 
9.4.1.6  Assessment of Adverse Event  Severity  
The determination  of adverse event severity rests on medical judgment of a medically - 
qualified Investigator. The severity of  AEs will be graded using the following definitions:  
• Mild: Awareness of sign, symptom, or event, but easily  tolerated.  
• Moderate: Discomfort enough t o cause interference with usual activity and may 
warrant  intervention. 
• Severe: Incapacitating with inability to do usual activities or significantly affects 
clinical status and warrants  intervention. 
 
9.4.1.7  Expectedness  
The expectedness of an AE or SAR shall be determined according to the most current 
Investigator’s  Brochure. Any AE that is not identified  in nature,  severity,  or specificity  in the 
current investigator’s brochure is considered unexpected. Events that are mentioned in the 
Investigator's Brochure as  occurring with a class of drugs or as anticipated from the 
pharmacological properties of the drug, but not specifically mentioned as occurring with the 
particular drug under investigation are considered  unexpected.  
 
9.4.2 Recording and Reporting of Adverse  Events  
The principal investigator, CEA and study team are responsible for monitoring the safety of participants enrolled into the trial. Events significant enough to necessitate discontinuation of study drug dosing will be captured on the AE electronic cas e report forms (eCRF).  
 
All AEs/SAEs, except for those anticipated AEs, occurring from signed informed consent to 14 (+/- 3 days)  after visit 3 will be captured  on the AE/SAE  eCRF.  Unless  exempted,  all SAEs, 
whether or not deemed drug- related or expected, must be reported by the investigator or 
qualified designee within 24 hours of first becoming aware of the event. For this study, all deaths will be reported on the SAE eCRF, as well as the Death eCRF page. The investigator or qualified designee will enter the required information regarding the AE/SAE into the appropriate module of the eCRF, which will be shared with the  CEA.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 27  
 When additional relevant information becomes available, the Investigator will record follow - 
up information according to the same process used for reporting the initial event as described 
above. The Investigator will follow all reportable events until resolution, stabilization or the 
event is otherwise explained. The investigators are also responsible for promptly reporting  
SAEs to the IRB per our institutional policy..  
 
9.4.3 Suspected Unexpected Serious Adverse  Reaction  
AEs that meet the criteria of serious, related to study drug, and unexpected per the Investigator’s Brochure, qualify for expedited reporting to the regulatory a uthorities. The PI 
will notify  the FDA  and all participating  investigators  in a written  IND safety  report  of an SAR 
that is serious and is unexpected, based on the opinion of the Adjudicator as soon as possible, but not later than 15 calendar days after t he event is confirmed to be a serious, unexpected SAR 
and qualifies for expedited reporting.  
 
 
10 Statistical Considerations  
10.1 Sample Size Calculations  
10.1.1 Primary Endpoint  
Data from several studies was used to determine the power to detect a difference in RHI with  
drug treatment.  In one study  of PAT reproducibility  in cardiovascular  patients,  the intra-patient 
standard  deviation  was 0.31.55 In a meta- analysis  of >1500  subjects  with cardiovascular  disease 
the mean RHI was 1.52.56 Based on these data, a sample size of 48 total subjects (24 
randomized each to ifetroban  or placebo)  is required  to detect  a 20% increase in RHI with over 
85% power  with a two-sided  alpha  of =0.05. Adjusting  for 10% loss to follow  up, we will need 
52 randomized subjects.  
10.1.2 Secondary Endpoints  
Data from  a preliminary  study  conducted at UMass  (Keaney,  unpublished  data)  in which  FMD 
was measured in patients after non -STEMI ACS was used for primary endpoint power 
calculations. In that pilot study, mean FMD was 9.6 ± 2.0% in normal controls (n=16) and  4.6 
± 2.8%  in ACS  patients  (n=22). Based  on these data,  a sample  size of 48 total subjects  (24 each 
randomized to ifetroban or placebo) is required to detect a 50% increase in FMD with 80% 
power  for an analysis  of covariance  of each treatment separately  with a two-sided  alpha=0.05. 
Data from the RIGOR study was used to determine the power to detect a difference in non - 
platelet TXA 2 generation with drug treatment.3 With a median 11 -dhTXB 2 of 330 pg/mg 
creatinine,  a 33% reduction  would be to 220 pg/mg  creatinine (reduction  from  5.8 to 5.4 in the 
natural  log scale)  with a s.d. of 0.55 in the log scale.  A sample  size of 48 total subjects  (24 each 
randomized to ifetroban or placebo) will have the ability to detect treatment group differences 
describ ed above with 80% power for an analysis of covariance of each treatment separately 
with a two -sided alpha=0.05, assuming an R2 = 0.50 with the baseline level and treatment 
included in the  model. 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 28  
 10.2 Statistical Analysis Plan  
Descriptive st atistics of patient characteristics will be generated using conventional methods. 
The main analysis of the outcome data will be a standard ANCOVA approach (SAS PROC 
GLM).  The full model  will be fit for change in RHI(or  other  measure of interest)  as the outcome 
for patient i based on treatment group (as two dummy (0,1) variables: x1, x2), a vector of patient 
characteristics  x3,I, and an error term ei: ln(11- dhTXB 2)i=b 0 + b1x1i + b2x2i + b3x3i +ei. We will test 
the main effects (treatment as well as patient characteristics) included in the model with the 
treatment main effects always included. We will investigate interactions between patient 
characteristics and treatments to provide insight into the effect of the se treatments on the 
outcomes overall and the effect in larger patient  subgroups.  
 
11 Data Management  
Study data will be recorded in a Research Electronic Data Capture (REDCap) database in the 
secure regulated environment at the UMass Medical School. REDCap is a secure, web -based 
application  designed  to support  data capture for research  studies,  providing  1) formatted  data entry 
screens; 2) audit trails; 3) automated export procedures for seamless data downloads to statistical 
packages; 4) procedures for importing data from external sources; and 5) an Application Programming  Interface that enables  it to communicate  with our web-based  randomization system. 
Data will be exported from REDCap into SAS (SAS Institute) for all analysis.  
 
12 Regulatory Issues  
12.1 Ethics  and Good Clinical  Practice 
This study will be carried out in compliance with the protocol. These procedures are designed  
to ensure adherence to Good Clinical Practice, as described in: 1) ICH Harmonized Tripartite Guidelines for Good Clinical Practice 1996, and; 2) US 21 Code of Federal Regulations dealing with clinical  studies  (including  parts  50 and 56 concerning  informed  consent  and IRB regulations). 
All investigators and study personnel agree to adhere to the instructions and procedures  described 
in it and hereby to adhere to the principles of Good Clinical Practice to which it  conforms.  
 
12.2 Institutional Review  Board  
Before  implementing  this study,  all required  documents  including  the protocol, proposed informed 
consent form and Investigator’s Brochure must be reviewed and approved by the UMMS IRB. Any amendments to the protocol, other than administrative ones, must be approved by this committee.  
 
12.3 Informed  Consent  
The investigator or designee must explain to each participant the nature of the study, its purpose, the procedures involved, the expected duration, the potential risks and benefits involved and any discomfort it may entail. Each participant must be informed that participation in the study is voluntary  and that he/she  may withdraw  from  the study  at any time and that withdrawal  of consent 
will not affect  his/her  subsequent  medical  treatment or relationship with the treating  physician.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 29  
 The informed consent form(s)and any amendments must be submitted by the investigator for  IRB 
approval . 
 
12.4 Quality Control and  Assurance  
All CRFs and corresponding office and clinical laboratory records for each subject will be 
periodically independently audited by personnel from the UMass Office of Clinical Research. These audits will help to verify the acc uracy and completeness of CRFs, to resolve any 
inconsistencies in the study records, and to assure that all protocol requirements, applicable FDA regulations, other requirements, and investigator’s obligations are being fulfilled. 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 30  
  
 
13 Reference s 
 
1. Kakouros N, Gluckman TJ, Conte J.V. et al. Differential impact of serial measurment of 
non-platelet thromboxane generation on long -term outcome after cardiac surgery. J Am 
Heart Assoc 2017;6(11):e007486. 
 
2. Kakouros N, Nazarian SM, Stadler PB, Kickler TS, Rade JJ. Risk factors for  non-platelet 
thromboxane generation after coronary artery bypass graft surgery. J Am Heart Assoc 
2016;5(3):e002615.  
 
3. Gluckman TJ, McLean RC, Schulman SP  et al. Effects of aspirin responsiveness and 
platelet reactivity on early ve in graft thrombosis after coronary artery bypass graft 
surgery. J Am Coll Cardiol  2011;57(9):1069- 1077. 
 
4. Patrono C, Ciabattoni G, Davi G. Thromboxane biosynthesis in cardiovascular  diseases. 
Stroke 1990;21(12 Suppl):IV130- IV133.  
 
5. Capra V, Back M, Angiolillo DJ, Cattaneo M, Sakariassen KS. Impact of vascular 
thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, 
and inflammation. J Thromb Haemost  2014;12(2):126- 137. 
 
6. Roberts LJ, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem 1981;256(16):8384- 8393. 
 
7. Fritsma  GA, Ens GE, Alvord MA, Carroll  AA, Jensen  R. Monitoring  the antiplatelet 
action of aspirin. JAAPA 2001;14(5):57- 62. 
 
8. Catella F, Nowak J, FitzGerald GA. Measurement of renal and non -renal eicosanoid 
synthesis. Am J Med 1986;81(2B):23- 29. 
 
9. Huang JS, Ramamurthy SK, Lin X, Le Breton GC. Cell signalling through thromboxane A2 receptors. Cell Signal 2004;16(5):521- 533. 
 
10. Nakahata N, Takano H, Ohizumi Y. Thromboxane A2 receptor -mediated tonic  contraction 
is attributed to an activation of phosphatidylcholine -specific phospholipase C in rabbit 
aortic smooth muscles. Life Sci 2000;66(5):L -6. 
 
11. Santilli F, Mucci L, Davi G. TP receptor activation and inhibition in atherothrombosis: 
the paradigm of diabetes mellitus. Intern Emerg Med  2011;6(3):203- 212. 
 
12. Feletou M, Vanhoutte PM, Verbeuren TJ. The thromboxane/endoperoxide receptor  (TP): 
the common villain. J Cardiovasc Pharmacol  2010;55(4):317- 332. 
 
13. Sasaki M, Miyosa wa K, Ohkubo S, Nakahata N. Physiological significance of 
thromboxane A(2) receptor dimerization. J Pharmacol Sci  2006;100(4):263- 270. 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 31  
 14. Bauer J, Ripperger  A, Frantz S, Ergun S, Schwedhelm E, Benndorf RA. Pathophysiology 
of isoprostanes in the cardiovascular system: implications of isoprostane -mediated 
thromboxane A2 receptor activation. Br J Pharmacol  2014;171(13):3115- 3131. 
 
15. Liu CQ, Leung FP, Wong SL et al. Thromboxane prostanoid receptor activation impairs 
endothelial nitric oxide -dependent vasorelaxations: the role of Rho kinase. Biochem 
Pharmacol  2009;78(4):374- 381. 
 
16. Moss NG, Vogel PA, Kopple TE, Arendshorst WJ. Thromboxane -induced renal 
vasoconstriction is mediated  by the ADP -ribosyl  cyclase  CD38  and superoxide  anion. Am 
J Physiol Renal Physiol  2013;305(6):F830- F838.  
 
17. Ball SK, Field MC, Tippins JR. Regulation of thromboxane receptor signaling at  multiple 
levels by oxidative stress -induced stabilization, relocation and enhanced responsiveness. 
PLoS One  2010;5(9):e12798. 
 
18. Valentin F, Field MC, Tippins JR. The mechanism of oxidative stress stabilization of the 
thromboxane receptor in COS -7 cells. J Biol Chem  2004;279(9):8316- 8324. 
 
19. Del TS, Basta G, Lazzerini G, Chancharme L, Lerond L, De CR. Involvement of the  TP 
receptor in TNF -alpha -induced  endothelial tissue factor expression. Vascul Pharmacol 
2014;62(2):49- 56. 
 
20. Nakahata N. Thromboxane  A2: physiology/pathophysiology, cellular  signal  transduction 
and pharmacology. Pharmacol Ther  2008;118(1):18- 35. 
 
21. Bode M, Mackman N. Regulation of tissue factor gene expression in monocytes and 
endothelial cells: Thromboxane A2 as a new player. Vascul Pharmacol  2014;62(2):57- 62. 
 
22. Ueharaguchi Y, Honda T, Kusuba N et al. Thromboxane A2 facilitates IL -17A production 
from Vgamma4(+) gammadelta T cells and promotes psoriatic dermatitis in mice. J Allergy Clin Immunol 2018;142(2):680- 683. 
 
23. Touchberry CD, Silswal N, Tchikrizov V et al. Cardiac thromboxane A2 receptor activation does not directly induce cardiomyocyte hypertrophy but does cause cell  death 
that is prevented with gentamicin and 2- APB. BMC Pharmacol Toxicol  2014;15:73. 
 
24. Dorn GW, Becker MW. Thromboxane A2 stimulated signal transduction in vascular 
smooth muscle. J Pharmacol Exp Ther  1993;265(1):447- 456. 
 
25. Ali S, Davis MG, Becker MW, Dorn GW. Thromboxa ne A2 stimulates vascular  smooth 
muscle hypertrophy by up -regulating the synthesis and release of endogenous basic 
fibroblast growth factor. J Biol Chem  1993;268(23):17397- 17403. 
 
26. Wacker MJ, Kosloski LM, Gilbert WJ et al. Inhibition of thromboxane A2- induc ed 
arrhythmias and intracellular calcium changes in cardiac myocytes by blockade of the inositol trisphosphate pathway. J Pharmacol Exp Ther 2009;331(3):917- 924. 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 32  
 27. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin- resistant 
thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular 
death in patients at high risk for cardiovascular events. Circulation 2002;105(14):1650-  
1655. 
 
28. Ames PR, Batuca JR, Muncy IJ et al. Aspirin insensitive thromboxane generation  is 
associated with oxidative stress in type 2 diabetes mellitus. Thromb Res 
2012;130(3):350- 354. 
 
29. Eikelboom JW, Hankey GJ, Thom J et al. Incomplete Inhibition of Thromboxane 
Biosynthesis  by Acetylsalicylic  Acid.  Determinants  and Effect  on Cardio vascular  Risk. 
Circulation  2008;118(1689):1690. 
 
30. McCullough PA, Vasudevan A, Sathyamoorthy M et al. Urinary 11 -Dehydro - 
Thromboxane  B2 and Mortality  in Patients  With Stable  Coronary  Artery  Disease.  Am J 
Cardiol  2017;119(7):972- 977. 
 
31. Antiplatelet Trialists'  Collaboration. Collaborative overview of randomised trials of 
antiplatelet therapy -II:Maintenance of vascular graft or arterial patency by  antiplatelet 
therapy. BMJ  1994;308(159):168. 
 
32. Faraday N, Becker DM, Yanek LR et al. Relation between atherosclerosis  risk factors  and 
aspirin resistance in a primary prevention population. Am J Cardiol  2006;98(6):774- 779. 
 
33. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection 
by thrombelastograph platelet mapping and validation by conv entional aggregometry 
using arachidonic acid stimulation. J Am Coll Cardiol  2005;46(9):1705- 1709. 
 
34. Homorodi N, Kovacs EG, Lee S et al. The lack of aspirin resistance in patients  with 
coronary artery disease. J Transl Med  2016;14:74. 
 
35. Kovacs EG, Katona E, Bereczky Z et al. New direct and indirect methods for the 
detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance  among 
healthy individuals. Thromb Res  2013;131(4):320- 324. 
 
36. Milne GL, Yin H, Hardy KD, Davies SS, Roberts LJ. Isoprostane generation  and 
function. Chem Rev 2011;111(10):5973- 5996.  
 
37. Schror K. Prostaglandins, other eicosanoids and endothelial cells. Basic Res  Cardiol 
1985;80(5):502- 514. 
 
38. Feletou M, Huang Y, Vanhoutte PM. Vasoconstrictor prostanoids. Pflugers Arch 
2010; 459(6):941- 950. 
 
39. Schulz E, Anter E, Keaney JF, Jr. Oxidative stress, antioxidants, and endothelial  function. 
Curr Med Chem  2004;11(9):1093- 1104.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 33  
 40. Hou X, Gobeil F, Jr., Peri K et al. Augmented vasoconstriction and thromboxane 
formation by 15 -F(2t)- isoprostane (8- iso-prostaglandin F(2alpha)) in immature pig 
periventricular brain microvessels. Stroke  2000;31(2):516- 524. 
 
41. Lahaie I, Hardy P, Hou X et al. A novel mechanism for vasoconstrictor action of 8-  
isoprostaglandin F2 alpha on retinal ves sels. Am J Physiol 1998;274(5 Pt  2):R1406-  
R1416. 
 
42. Morrow JD, Awad JA, Wu A, Zackert WE, Daniel VC, Roberts LJ. Nonenzymatic free 
radical -catalyzed generation of thromboxane -like compounds (isothromboxanes) in vivo. 
J Biol Chem  1996;271(38):23185- 23190. 
 
43. Cayatte AJ, Du Y, Oliver -Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The 
thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E - 
deficient mice: evidence that eicosanoids other than thromboxane contribute to 
atherosclero sis. Arterioscler Thromb Vasc Biol 2000;20(7):1724- 1728.  
 
44. Bode M, Mackman N. Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane A2 as a new player. Vascul Pharmacol  2014;62(2):57- 62. 
 
45. Kapur NK, Deming CB, Kapur S et  al. Hemodynamic modulation of endocardial 
thromboresistance. Circulation  2007;115(1):67- 75. 
 
46. Kapur NK, Bian C, Lin E et al. Inhibition of transforming growth factor -beta restores 
endothelial thromboresistance in vein grafts. J Vasc Surg  2011;54(4):1117- 1123. 
 
47. Sohn RH, Deming CB, Johns DC et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated via activation of nuclear  factor -kappa 
B. Blood 2005;105:3910- 3917. 
 
48. Hiroi T, Deming CB, Zhao H et al. Prot easome Inhibitors Enhance Endothelial 
Thrombomodulin Expression via Induction of Kruppel -Like Transcription  Factors. 
Arterioscler Thromb Vasc Biol 2009;29(10):1587- 1593. 
 
49. Harding SD, Sharman JL, Faccenda E et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 201 8: updates and expansion to encompass the new guide  to 
IMMUNOPHARMACOLOGY. Nucleic Acids Res  2018;46(D1):D1091- D1106. 
 
50. Sakariassen KS, Alberts P, Fontana P, Mann J, Bounameaux H, Sorensen AS. Effect of 
pharmaceutical interventions targeting thromboxane rec eptors and thromboxane  synthase 
in cardiovascular and renal diseases. Future Cardiol  2009;5(5):479- 493. 
 
51. Boffa  JJ, Just A, Coffman  TM, Arendshorst  WJ. Thromboxane  receptor  mediates  renal 
vasoconstriction and contributes to acute renal failure in endotoxemic mice. J Am Soc Nephrol  2004;15(9):2358- 2365. 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 34  
 52. Xu S, Jiang B, Maitland KA et al. The thromboxane receptor antagonist S18886 
attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E -deficient  mice. 
Diabetes  2006;55(1):110 -119. 
 
53. Smith SR, Creech EA, Schaffer AV et al. Effects of thromboxane synthase inhibition with 
CGS 13080 in human cyclosporine nephrotoxicity. Kidney Int  1992;41(1):199- 205. 
 
54. Rosenfeld L, Grover GJ, Stier CT, Jr. Ifetroban sodium: an effective TxA2/PGH2 
receptor antagonist. Cardiovasc Drug Rev  2001;19(2):97- 115. 
 
55. Nil M, Schafer D, Radtke T, Saner H, Wilhelm M, Eser P. Reproducibility of peripheral 
arterial tonometry measurements in male cardiovascular patients. Eur J Clin Invest 
2014;44(11):1065- 1071.  
 
56. Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A. Prognostic Value of Flow - 
Mediated Vasodilation in Brachial Artery and Fingertip  Artery for Cardiovascular Events: 
A Systematic  Review  and Meta- Analysis.  J Am Heart  Assoc  2015;4( 11). 
 
57. Widlansky ME, Gokce N, Keaney JF, Jr., Vita JA. The clinical implications of  endothelial 
dysfunction. J Am Coll Cardiol  2003;42(7):1149- 1160. 
 
58. Flammer  AJ, Anderson T, Celermajer  DS et al.  The assessment  of endothelial  function: 
from research into clinical practice. Circulation  2012;126(6):753- 767. 
 
59. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial -dependent flow -mediated vasodilation of the brachial artery: a report of the 
International Brachial Ar tery Reactivity Task Force. J Am Coll Cardiol 2002;39(2):257-  
265. 
 
60. Hamburg NM, Benjamin EJ. Assessment of endothelial function using digital  pulse 
amplitude tonometry. Trends Cardiovasc Med 2009;19(1):6- 11. 
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 35  
 14 Appendix A: Table of Study  Events  
 
 
 
Event  Screening  Visit  1 
Day 0 Visit 2  
Day 7±3  Visit 3  
Day 28±3  Visit 4  
Day 42±3  
Informed Consent  X     
Medical History  X     
Physical Exam   X  X  
Vital Signs   X  X  
Concomitant Medications  X X  X  
Study Drug Pill Counts   X  X  
AE Assessment   X X X X 
Vascular Studies       
FMD   X  Xa  
PAT   X  Xa  
Laboratory Studies       
UrineTXB 2-M X     
Urine Prostanoids (8 -iso- 
PGF 2α; 6-ketoPGF 1α; 2,3-  dinor -6-ketoPGF 1α)  
X  
X  
Urine Creatinine  X X  X  
Plasma ICAM -1; APC; TF   X  X  
Serum creatinine; hs-CRP; 
NT pro -BNP   X  X  
aPerformed while still on study drug.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 36  
 15 Appendix B: Brachial Reactivity  
15.1 Introduction  
Healthy blood vessels dilate in response to an increase in blood flow, a phenomenon known as 
flow-mediated dilation (FMD).57 FMD is predominantly a function of endothelial nitric oxide 
(NO) release that relaxes underlying vascular smooth muscle cells. Endothelial release of PGI 2 
also plays a role in mediating FMD. TXA 2, in addition to being a potent platelet activator, is 
also a potent vasoconstrictor that antagonizes the effects of NO and PGI 2. 
 
Vascular dysfunction is associated with the development and presence of atherosclerosis and 
characterized by an impaired vasodilatory response to blood flow. FMD is traditionally 
measured non -invasively by ultrasound in the brachial artery following a period of blood flow 
cessation caused by an inflated blood pressure cuff.58 Typically, the cuff is inflated to at least 
50 mm Hg above systolic pressure to occlude arterial inflow for 5 minutes. This  
causes ischemia and consequent dilation of downstream resistance vessels via autoregulatory 
mechanisms. Subsequent cuff deflation induces a brief high- flow state through the brachial 
artery (reactive hyperem ia) to accommodate the dilated resistance vessels. The resulting 
increase in shear stress causes the brachial artery to dilate. The ratio of the brachial arter y 
diameter after the occlusive period to that at baseline is recorded as the percent FMD. Impaired FMD is associated with cardiovascular risk factors and the development of clinical 
cardiovascular disease. The protocol that will be used is based on guideli nes published by the 
American College of Cardiology.
59 
15.2 Protocol  
15.2.1  Subject  preparation  
1. Prior to the study, ensure the patient has fasted for at least 4 hours, and has  refrained 
for at least 8 hours from caffeine, tobacco, vitamins or medications that might affect 
vascular tone. The patient may wish to use the restroom prior to the  study.  
2. The brachial reactivity study will be conducted in a quiet, dimly lit, temperature - 
controlled exam room to reduce fluctuations in vascular  tone.  
3. Cell phones or paging devic es should be silenced, and restrictive clothing that  could 
interfere with blood flow to the arms should be removed. The patient should also 
remove watches, rings, or other jewelry on the hands or  fingers.  
4. The patient should be supine and comfortable for 15 minutes so as to attain a cardiovascular steady -state. Place the two arm supporters along each of the  patient's 
sides.  
5. Place a blood pressure cuff on the arm to be occluded during the brachial reactivity study. Apply the cuff snugly, but without excess pr essure. Do not inflate the cuff  at 
this time.  
6. The brachial artery is imaged above the antecubital fossa in the longitudinal plane (Fig. 1 ) using a linear array transducer with a minimum frequency of 7 MHz, attached 
to a high- quality ma inframe ultrasound system.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 37  
 7. A segment with clear anterior and posterior intimal interfaces between the lumen 
and vessel wall is selected for continuous 2D grayscale imaging. During image 
acquisition, anatomic landmarks such as veins and fascial planes are noted to help 
maintain the same image of the artery throughout the study. A stereotactic probe - 
holding device can be  helpful. 
 
 
 
Figure 1 . Ultrasound image of the brachial artery (longitudinally) at 8× 
magnification, 11- MHz transducer  frequency annotated for anatomic  
landmarks.  
 
15.2.2  Conduct of the Brachia l Reactivity Study  
 
1. Tell the patient that you are going to inflate the cuff for the occlusion phase and that he  or 
she should stay relaxed and not move the  fingers.  
 
2. Rapidly inflate the blood pressure cuff to a supra -systolic pressure of 60mmHg above  the 
patient's systolic pressure or 200mmHg, whichever is higher. A mid- artery pulsed 
Doppler signal is obtained to confirm cessation of blood flow.  
 
3. After 5 minutes, rapidly deflate the blood pressure cuff. A midartery pulsed Doppler 
signal is obtained upon imm ediate cuff release and no later than 15 s after cuff  deflation 
to assess hyperemic velocity.  

Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 38  
  
 
15.3 Representative  Results  
4.  
Figure 2 . Schematic drawing of ultrasound imaging of the brachial artery and representative 
normal and abnormal results.  
 
16 Appendix C: Peripheral Arterial  Tonometry  
16.1 Introduction  
Assessment of digital vasodilator responses using a commercially -available fingertip  peripheral 
arterial tonometry (PAT) device (EndoPAT; Itamar Medical LTD, Caesarea, Israel) is a novel 
measure of vascular function that provides different but complimentary information compared 
with FMD.60With this device, a beat -to-beat plethysmographic record of the finger arterial 
pulse wave amplitude is captured using pneumatic probes placed on t he index finger of each 
hand (Figure 1). The same reactive hyperemia technique that is used to measure FMD is used 
for Endo- PAT and the two techniques can be performed simultaneously. The baseline digital 
pulse amplitude is a measure of local arterial tone  in the fingertip. The PAT ratio records post - 
ischemic arterial responsiveness to reactive hyperemia produced by a cuff occlusion in the 
forearm.  

Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 39  
  
 
 
 
Figure 1. The Endo -PAT device.  
 
16.2 Protocol  
16.2.1 Subject  Preparation  
1. Prior to the study, ensure the patient has fasted for at least 4 hours, and has  refrained 
for at least 8 hours from caffeine, tobacco, vitamins or medications that might affect 
vascular tone. The patient may wish to use the restroom prior to the  study.  
2. The Endo- PAT study will be conducted in a quiet, dimly lit, temperature -controlled 
exam room to reduce fluctuations in vascular  tone. 
3. Cell phones or paging devices should be silenced, and restrictive clothing that could 
interfere with blood flow to the arms should be removed. The patie nt should also 
remove watches, rings, or other jewelry on the hands or  fingers.  
4. Inspect the patient's fingers for any deformities or injuries that could affect the study. Do not place the probes on a finger that is cut or injured. Fingernails should not extend more than 5mm or 1/5 of an inch beyond the tip of the finger tissue. Trim or 
file fingernails if necessary to avoid damaging the internal membranes of the PAT 
probes and displacing the finger from the sensing region of the  probe.  

Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 40  
 5. The index finger is recommended for the study; however, if this finger is unsuitable, a 
different digit (except the thumb) may be used, as long as the same finger is used on 
both hands. 
6. The patient should be supine and comfortable for 15 minutes so as to attain a  
cardiovascular steady -state. Place the two arm supporters along each of the  patient's 
sides.  
7. Measure the blood pressure using the control arm (the arm that is not occluded during 
the Endo- PAT  study.  
8. Place a blood pressure cuff on the arm to be occluded du ring the Endo- PAT study. 
Apply the cuff snugly, but without excess pressure. Do not inflate the cuff at this  time 
16.2.2 Prepare the Endo -PAT System for  Study  
1. Launch the Endo- PAT 2000 software and click the "Patient Information" icon on the 
tool bar to create a new patient  file. 
2. Complete the Patient Information dialog box, including patient ID, name  (optional), 
age, gender, height, weight, systolic and diastolic blood pressures. Optional fields allow for free text comments. Select your name from the pre- defined l ist in the 
Patographer name field. If your name has not been inserted add it the list and  select.  
3. Select two new PAT probes and connect to the pneumo- electrical tubing. To  connect 
the probes, insert the connector tab into the probe slit and gently press the connector onto the probe until it clicks into place.  
4. Place the connected probes into the sockets of the arm -supports and press  the 
"Deflate" button on the top of the Endo- PAT 2000 device.  
16.2.3 Conduct of the Endo -PAT  Study  
1. Place the patient’s index fingers co mpletely into the probes, confirm with the patient 
that he or she can feel the very end of the probes, and press the "Inflate" button on the top of the Endo- PAT 2000 device.  
2. Place a foam anchor ring at the base of the adjacent middle finger. Ensure that t he 
foam ring and the PAT sensor do not touch. Otherwise the ring may mechanically interfere with the  sensor.  
3. Create an approximately 7 -10cm loop with the pneumo- electrical tubing. The loop 
should extend from the PAT sensor and return to the foam ring on the adjacent  finger 
while the rest of the tubing that connects to the EndoPAT device is pointing out tubing to the tip of the  finger.  
4. Position the patient's arms so the forearms are supported on the arm supports and the fingers dangle freely off the edge of the support. Make sure the probes are not in contact with any object, including the arm support, foam ring, tubing, the mattress  or 
another  finger.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 41  
 5. Ask the patient to refrain from moving the fingers, as this will create mechanical 
artifacts. It is important for the patient to be relaxed throughout the study. Explain to 
the patient that during the test you will inflate the arm cuff, and during that time  they 
may feel some discomfort, numbness, or  tingling.  
6. Click the "Standby" icon on the Endo- PAT's computer interface. Adjust the time  base 
to 1 minute and adjust the signal gain on the screen to maximize signal clarity. 
Inspect the tracings of the PAT signals from the two probes to confirm that they are free of artifactual signals. If artifactual signals are present, veriify that the probes are not touching anything and that the patient is not moving the  fingers.  
7. To begin the study, click the "Go" icon on the computer interface. Start the stopwatch, by clicking the "Start/Stop Timer" icon. This will initiate a five minute count down for the baseline recording period. After five minutes, stop the  stopwatch 
by clicking the "Start/Stop Timer"  icon.  
8. Tell the patient that you are going to inflate the cuff for the occlusion phase and that 
he or she should stay relaxed and not move the  fingers.  
9. Rapidly inflate the blood pressure cuff to a supra -systolic pressure of 60mmHg  above 
the patient's systolic pressure or 200mmHg, whichever is higher and start the stopwatch again. Complete cessation of blood flow to the hand is verified by the absence of a PAT signal from the occluded arm. To confirm occlusion increase the gain on the screen of the channel of the occluded side to 20,000 while keeping the gain of the contra -lateral side constant. Decrease the time base of both channels to 30 
seconds. Verify that you do not observe any signals at a periodicity that matches the signal from the control arm as this indicates an incomplete occlusion. If this is the case then further inflate the cuff until no signals are seen . The cuff may be inflated to 
a maximum of  300mmHg.  
10. This will initiate a five minute count down for the arterial occlusion recording  period. 
Toward the end of the occlusion period tell the patient you are going to release the cuff and that they should cont inue to refrain from moving their fingers. After exactly 
five minutes, deflate the cuff abruptly as quickly as possible and stop the stopwatch by clicking the "Start/Stop Timer"  icon.  
11. Click the "Start/Stop Timer" icon again to initiate a five -minute post occlusion 
recording period. Stop the timer after five minutes and click the "Test Stop" icon  to 
complete the study. The probes will automatically  deflate.  
12. Remove the probes, tape, and foam rings from the patient's fingers and disconnect  the 
PAT probes from the pneumo- electrical tubing. Discard the used  probes.  
 
16.2.4 Review and  Analysis 
1. Load the study file to the screen using the load icon. To run the automatic analysis, click the "magician stick" icon. The occlusion period will be highlighted in blue  and 
the test  result will be displayed, including the Reactive Hyperemia Index (RHI) and 
Heart Rate (HR), in the right -hand column of the  screen.  
Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 42  
 2. To review additional data, including study parameters, calculated variables, patient 
information, and measure s of signal quality, click the "Open Results of Last 
Calculation" icon. This will open a spread sheet with study parameters and results  for 
all analyses performed to date, with the last line in the table containing data from the 
most recent  analysis.  
16.3 Repre sentative  Results  
A representative Endo -PAT screen of a study performed on an individual with normal 
endothelial vasodilator function is shown in Figure 2 and a representative screen performed on 
an individual with endothelial vasodilator dysfunction is shown in Figure 3. 
 
Figure 2: Normal Endothelial Vasodilator Function. Representative recording of an individual with normal endothelial vasodilator function, characterized by an increase in the signal amplitude after cuff release relative to baseline.  
 
 

Protocol H00017901  Version 5, August 2022  
CONFIDENTIAL  Page 43  
  
Figure 3: Abnormal Endothelial Vasodilator Function. Representative 
recording of an individual with abnormal endothelial vasodilator function, 
characterized by lack of increase in the signal amplitude after cuff release relative to baseline . 